Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review
Anthony Muchai Manyara(University of Bristol), Oriana Ciani(Bocconi University), Philippa Davies(University of Bristol), Sylwia Bujkiewicz(University of Leicester), Joseph S. Ross(Yale University), Dalia Dawoud(Cairo University), An‐Wen Chan(World Health Organization), Mario Ouwens(AstraZeneca (Sweden)), Gary S. Collins(NIHR Birmingham Biomedical Research Centre), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Derek Stewart, Nancy J. Butcher(University of Toronto), Valerie Wells(MRC/CSO Social and Public Health Sciences Unit), Amber Young(University of Bristol), Christopher J. Weir(University of Edinburgh), Rod S Taylor(University of Southern Denmark), Martin Offringa(Hospital for Sick Children)
Cited by 30
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist
|PLoS Medicine|2014|2k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
|Annals of the Rheumatic Diseases|2020|1.7k